HeartSciences (HSCS) Receivables (2022 - 2025)
HeartSciences posted quarterly Receivables of $4350.0 for Q2 2025, down 70.41% on a QoQ basis from $14700.0 in Q1 2024.
HeartSciences (HSCS) has 4 years of Receivables data on file, last reported at $4350.0 in Q2 2025.
- For the quarter ending Q2 2025, Receivables changed N/A year-over-year to $4350.0; the trailing twelve-month figure through Apr 2025 stood at $4350.0 (changed N/A YoY), and the FY2025 full-year result was $4350.0, changed N/A from the prior year.
- Receivables for Q2 2025 stood at $4350.0, down from $14700.0 in the prior quarter.
- Across five years, Receivables topped out at $14700.0 in Q1 2024 and bottomed at $2321.0 in Q2 2022.
- The 4-year median for Receivables is $4125.0 (2023), against an average of $6317.8.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 8.21 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 3.57 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.36 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 3.15 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 973.00 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 3.82 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 1.11 Bn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 4.50 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 1.09 Bn |
| 10 | HeartSciences | 4.56 Mn | 1.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2025 | 4,350.00 |
| Jan 31, 2024 | 14,700.00 |
| Oct 31, 2023 | 3,900.00 |
| Apr 30, 2022 | 2,321.00 |